Cargando…
Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
BACKGROUND: The neoadjuvant use of immune checkpoint inhibitor combined with chemotherapy (nICT) or chemoradiotherapy (nICRT) in locally advanced esophageal cancer (EC) is currently an area of active ongoing research. Therefore, we carried out a comprehensive meta-analysis to compare the efficacy an...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076616/ https://www.ncbi.nlm.nih.gov/pubmed/37033991 http://dx.doi.org/10.3389/fimmu.2023.1108213 |
_version_ | 1785020169499705344 |
---|---|
author | Qin, Hao Liu, Futao Zhang, Yaozhong Liang, Yuxiang Mi, Yuan Yu, Fan Xu, Haidi Li, Kuankuan Lin, Chenxi Li, Lei Tian, Ziqiang Wang, Lei |
author_facet | Qin, Hao Liu, Futao Zhang, Yaozhong Liang, Yuxiang Mi, Yuan Yu, Fan Xu, Haidi Li, Kuankuan Lin, Chenxi Li, Lei Tian, Ziqiang Wang, Lei |
author_sort | Qin, Hao |
collection | PubMed |
description | BACKGROUND: The neoadjuvant use of immune checkpoint inhibitor combined with chemotherapy (nICT) or chemoradiotherapy (nICRT) in locally advanced esophageal cancer (EC) is currently an area of active ongoing research. Therefore, we carried out a comprehensive meta-analysis to compare the efficacy and safety of the new strategy with routine neoadjuvant strategy, which included neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT). PATIENTS AND METHODS: MEDLINE (via PubMed), Embase (via OVID), ISI Web of Science database and Cochrane Library were included. And, all of them were searched for eligible studies between January, 2000 and February, 2023. The pathological complete response (pCR) and major pathological response (MPR) were primary outcome of our study. The second outcome of interest was R0 resection rate. Odds ratio (OR) and associated 95% CI were used as the effect indicators comparing the safety and efficiency of the neoadjuvant immunotherapy with the routine neoadjuvant therapy. Fixed-effect model (Inverse Variance) or random-effect model (Mantel-Haenszel method) was performed depending on the statistically heterogeneity. RESULTS: There were eight trials with 652 patients were included in our meta-analysis. The estimated pCR rate was higher in the neoadjuvant immunotherapy group (OR =1.86; 95% CI, 1.25–2.75; I(2) = 32.8%, P=0.166). The different results were found in the esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) subgroups, the estimated OR was 2.35 (95%CI, 1.00–2.72; I(2) = 30.9%, P=0.215) in the EAC subgroup, and 2.35 (95% CI, 1.20–4.54; I(2) = 45.3%, P=0.161) in the ESCC subgroup, respectively. The neoadjuvant immunotherapy also showed the advantage in the MPR rates (OR =2.66; 95% CI, 1.69–4.19; I(2) = 24.3%, P=0.252). There was no obvious difference between the neoadjuvant immunotherapy and routine neoadjuvant therapy with respect to surgical resection rate, R0 resection rate, surgical delay rate; while more treatment-related adverse events were observed for the neoadjuvant immunotherapy for pneumonitis/pneumonia (OR=3.46, 95% CI, 1.31–9.16; I(2) = 67.3%, P=0.005) and thyroid dysfunction (OR=4.69, 95% CI, 1.53–14.36; I(2) = 56.5%, P=0.032). CONCLUSION: The pooled correlations indicated that the neoadjuvant immunotherapy (both nICT and nICRT) could significantly increase the rates of pCR and MPR, compared with routine neoadjuvant therapy (both nCT and nCRT) in the treatment of locally advanced EC. The neoadjuvant immunotherapy and routine neoadjuvant therapy were with acceptable toxicity. However, randomized studies with larger groups of patients need to performed to confirm these results. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42020155802. |
format | Online Article Text |
id | pubmed-10076616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100766162023-04-07 Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis Qin, Hao Liu, Futao Zhang, Yaozhong Liang, Yuxiang Mi, Yuan Yu, Fan Xu, Haidi Li, Kuankuan Lin, Chenxi Li, Lei Tian, Ziqiang Wang, Lei Front Immunol Immunology BACKGROUND: The neoadjuvant use of immune checkpoint inhibitor combined with chemotherapy (nICT) or chemoradiotherapy (nICRT) in locally advanced esophageal cancer (EC) is currently an area of active ongoing research. Therefore, we carried out a comprehensive meta-analysis to compare the efficacy and safety of the new strategy with routine neoadjuvant strategy, which included neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT). PATIENTS AND METHODS: MEDLINE (via PubMed), Embase (via OVID), ISI Web of Science database and Cochrane Library were included. And, all of them were searched for eligible studies between January, 2000 and February, 2023. The pathological complete response (pCR) and major pathological response (MPR) were primary outcome of our study. The second outcome of interest was R0 resection rate. Odds ratio (OR) and associated 95% CI were used as the effect indicators comparing the safety and efficiency of the neoadjuvant immunotherapy with the routine neoadjuvant therapy. Fixed-effect model (Inverse Variance) or random-effect model (Mantel-Haenszel method) was performed depending on the statistically heterogeneity. RESULTS: There were eight trials with 652 patients were included in our meta-analysis. The estimated pCR rate was higher in the neoadjuvant immunotherapy group (OR =1.86; 95% CI, 1.25–2.75; I(2) = 32.8%, P=0.166). The different results were found in the esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) subgroups, the estimated OR was 2.35 (95%CI, 1.00–2.72; I(2) = 30.9%, P=0.215) in the EAC subgroup, and 2.35 (95% CI, 1.20–4.54; I(2) = 45.3%, P=0.161) in the ESCC subgroup, respectively. The neoadjuvant immunotherapy also showed the advantage in the MPR rates (OR =2.66; 95% CI, 1.69–4.19; I(2) = 24.3%, P=0.252). There was no obvious difference between the neoadjuvant immunotherapy and routine neoadjuvant therapy with respect to surgical resection rate, R0 resection rate, surgical delay rate; while more treatment-related adverse events were observed for the neoadjuvant immunotherapy for pneumonitis/pneumonia (OR=3.46, 95% CI, 1.31–9.16; I(2) = 67.3%, P=0.005) and thyroid dysfunction (OR=4.69, 95% CI, 1.53–14.36; I(2) = 56.5%, P=0.032). CONCLUSION: The pooled correlations indicated that the neoadjuvant immunotherapy (both nICT and nICRT) could significantly increase the rates of pCR and MPR, compared with routine neoadjuvant therapy (both nCT and nCRT) in the treatment of locally advanced EC. The neoadjuvant immunotherapy and routine neoadjuvant therapy were with acceptable toxicity. However, randomized studies with larger groups of patients need to performed to confirm these results. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42020155802. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076616/ /pubmed/37033991 http://dx.doi.org/10.3389/fimmu.2023.1108213 Text en Copyright © 2023 Qin, Liu, Zhang, Liang, Mi, Yu, Xu, Li, Lin, Li, Tian and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Qin, Hao Liu, Futao Zhang, Yaozhong Liang, Yuxiang Mi, Yuan Yu, Fan Xu, Haidi Li, Kuankuan Lin, Chenxi Li, Lei Tian, Ziqiang Wang, Lei Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title | Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title_full | Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title_fullStr | Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title_full_unstemmed | Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title_short | Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis |
title_sort | comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: a systematic review and meta-analysis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076616/ https://www.ncbi.nlm.nih.gov/pubmed/37033991 http://dx.doi.org/10.3389/fimmu.2023.1108213 |
work_keys_str_mv | AT qinhao comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT liufutao comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT zhangyaozhong comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT liangyuxiang comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT miyuan comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT yufan comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT xuhaidi comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT likuankuan comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT linchenxi comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT lilei comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT tianziqiang comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis AT wanglei comparisonofneoadjuvantimmunotherapyversusroutineneoadjuvanttherapyforpatientswithlocallyadvancedesophagealcancerasystematicreviewandmetaanalysis |